Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453591 | Lung Cancer | 2018 | 24 Pages |
Abstract
The molecular characteristics of de novo T790âM carriers differ distinctly from acquired T790âM carriers. The RAF of EGFR T790âM mutation may serve as a predictive biomarker for treatment response to EGFR-TKIs. Osimertinib is potentially an effective drug for the treatment of NSCLC with de novo T790âM.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Panwen Tian, Ye Wang, Weiya Wang, Yalun Li, Ke Wang, Xiaowei Cheng, Yuan Tang, Han Han-Zhang, Junyi Ye, Shannon Chuai, Weimin Li,